Latest news with #SoumitRoy
Yahoo
2 days ago
- Business
- Yahoo
JonesTrading Remains Bullish on Janux Therapeutics (JANX) With a $90 Price Target
Janux Therapeutics, Inc. (NASDAQ:JANX) is one of the 13 Small Cap Stocks Analysts Are Bullish On. On May 14, JonesTrading analyst Soumit Roy maintained a bullish stance on Janux Therapeutics, Inc. (NASDAQ:JANX), giving it a Buy rating with a $90 price target. The analyst based the rating on the company's promising developments and future potential. A rack of test tubes and beakers being stirred in a laboratory, as researchers analyze the data. Janux Therapeutics, Inc. (NASDAQ:JANX) is expected to release additional data from its Phase 1 trials for JANX007 and JANX008 in H2 2025, which the analyst projects could affect its market position. JANX007, a T cell-engaging antibody, is expected to be in competition with Pluvicto. Despite a complicated administration, Pluvicto already holds a considerable market share. However, the analyst reasoned that JANX007 could experience faster market adoption if it exhibits efficacy comparable to Pluvicto, which would positively impact Janux Therapeutics, Inc. (NASDAQ:JANX). The analyst also noted that the safety profile of JANX007 would be critical, especially in regard to steroid use post-CRS resolution. Therefore, Roy reasoned that investor interest could grow with a favorable safety outcome. Janux Therapeutics, Inc. (NASDAQ:JANX) is a preclinical stage biopharmaceutical company that develops therapeutics based on the Tumor Activated T Cell Engager platform technology. The company develops tumor-activated immunotherapies for cancer through two bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). While we acknowledge the potential of JANX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 days ago
- Business
- Yahoo
JonesTrading Remains Bullish on Janux Therapeutics (JANX) With a $90 Price Target
Janux Therapeutics, Inc. (NASDAQ:JANX) is one of the 13 Small Cap Stocks Analysts Are Bullish On. On May 14, JonesTrading analyst Soumit Roy maintained a bullish stance on Janux Therapeutics, Inc. (NASDAQ:JANX), giving it a Buy rating with a $90 price target. The analyst based the rating on the company's promising developments and future potential. A rack of test tubes and beakers being stirred in a laboratory, as researchers analyze the data. Janux Therapeutics, Inc. (NASDAQ:JANX) is expected to release additional data from its Phase 1 trials for JANX007 and JANX008 in H2 2025, which the analyst projects could affect its market position. JANX007, a T cell-engaging antibody, is expected to be in competition with Pluvicto. Despite a complicated administration, Pluvicto already holds a considerable market share. However, the analyst reasoned that JANX007 could experience faster market adoption if it exhibits efficacy comparable to Pluvicto, which would positively impact Janux Therapeutics, Inc. (NASDAQ:JANX). The analyst also noted that the safety profile of JANX007 would be critical, especially in regard to steroid use post-CRS resolution. Therefore, Roy reasoned that investor interest could grow with a favorable safety outcome. Janux Therapeutics, Inc. (NASDAQ:JANX) is a preclinical stage biopharmaceutical company that develops therapeutics based on the Tumor Activated T Cell Engager platform technology. The company develops tumor-activated immunotherapies for cancer through two bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). While we acknowledge the potential of JANX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
17-05-2025
- Business
- Yahoo
Enliven price target lowered to $27 from $36 at JonesResearch
JonesResearch analyst Soumit Roy lowered the firm's price target on Enliven (ELVN) to $27 from $36 and keeps a Buy rating on the shares. The company's abstract from the Phase 1 late line chronic myeloid leukemia trial with ELVN-001 'was met with a lukewarm initial stock reaction that weakened over time,' the analyst tells investors in a research note. The firm says that even though ELVN-001 showed efficacy and safety profile inline with the September 2024 update with two-times the patient population, the market treated the stock with a sell on news approach. Jones sees ELVN-001 performing at least inline with Novartis' Scemblix. Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders' Hot Stocks on TipRanks >> Read More on ELVN: Disclaimer & DisclosureReport an Issue Enliven Therapeutics' ELVN-001: Promising Competitor in the $3 Billion Late Line CML Market Enliven Therapeutics Reports Q1 Results and Pipeline Progress Enliven price target raised to $40 from $39 at H.C. Wainwright Enliven Therapeutics: Strategic Focus and Promising Developments Justify Buy Rating Positive Buy Rating for Enliven Therapeutics Driven by Promising Phase 1 Results of ELVN-001 in CML Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
